Illumina (NASDAQ: ILMN) reported Q3 EPS of $0.77, $0.21 better than the analyst estimate of $0.56. Revenue for the quarter came in at $481 million versus the consensus estimate of $451.2 million.

Illumina sees FY2014 EPS of $2.63-$2.65, versus the consensus of $2.30.

“Illumina experienced tremendous momentum in the third quarter, with strong shipments in HiSeq X, NextSeq and MiSeq, as well as the associated consumables, resulting in record financial results,” stated Jay Flatley, CEO. “With the most extensive sequencing portfolio available, we are well-positioned for continued long-term growth as we develop and address the large and untapped market opportunities ahead of us.”

For earnings history and earnings-related data on Illumina (ILMN) click here.